NovoCure Ltd.'s Optune was shown to improve overall survival at two, three, four and five years for patients with newly diagnosed glioblastoma, or GBM, when added to standard temozolomide chemotherapy in a phase 3 trial.
Under the 40-month trial involving 695 patients with newly diagnosed GBM, the two-year survival rate increased to 43% for those treated with Optune together with temozolomide compared to 30% for those treated with temozolomide alone.
The five-year survival rate also increased to 13% for patients treated with Optune combined with temozolomide compared to 5% for those treated with temozolomide exclusively.
The trial concluded that combining Optune with temozolomide resulted in a statistically significant extension of the median overall survival of patients with newly diagnosed GBM to 21 months. The results are the best reported so far for newly diagnosed GBM in a phase 3 trial, Novocure said in a news release.
GBM is the most common form of primary brain cancer. About 12,500 people are diagnosed with the disease in the U.S. each year.